Table 2. SAT combinations, prior surgical intervention, VA test, VF test and prognostic factors on decrease of VA.
| Author (year) | SAT (N) | Previous TX (N) | Visual tools | VF: type of test | Change in VF after SAT | Prognostic factors on decrease of VA |
|---|---|---|---|---|---|---|
| Massimino et al. (2002) [17] | Cispl—ETO (34)b | ND | ND | - | ND | ND |
| Dalla Via et al. (2007) [41] | CB-VC | No | TAC, LH, Snellen | ND | ND | ND |
| Massimino et al. (2010) [42] | Cispl- ETO (37)A | Prior CT/ RT: no, SX: ND | ND | - | ND | ND |
| Shofty et al. (2011) [43] | CB- VC (19) | No | Snellen, self-made grading system | - | ND | ND |
| Fisher et al. (2012) [30] | CB-VC (105), CB (9), VB (1) | Biopsy + (ND), SX: ND, prior CT/RT: excluded | TAC, Lea, HOTV, Snellen | ND | Total population: 5 (19%) improved, 10 (38%) remained stable, 11 (42%) decreased. No definition of change | Location in optic tracts/radiation: (OR 3.0; 95% CI: 1.1–8.3; P = 0.032) |
| Kalin-Hadju et al. (2014) [31] | CB-VC (7), CB (4), CB-VB (2), CP (2), TPCV (1), VC-AC (1) | 3/17 VD, prior CT/RT: ND | BFP, TAC, Allen card, Snellen | - | ND | ND |
| Dodgshun et al. (2015) [9] | CB (38), CB-VC (4 )B | Biopsy + (ND), SX/ RT: ND | Snellen, Kay Pictures | ND | 7/35 (20%) abnormalities at diagnosis: 2/ 7 (29%) improved, 5/7 (71%) stable (no definition of change) | ND |
| Prada et al. (2015) [44] | CB/VC (21), VC/DC (1)B | ND | ND | - | ND | ND |
| Doganis et al. (2016) [45] | CB-VC (16), of which switch to VB (5) due to allergy | ND | Snellen, Kay Pictures | - | ND | ND |
| Lassaletta et al. (2016)[18] | VB (24) | Previous sx/ biopsy + (ND) | ND | - | ND | ND |
| Falzon et al. (2018) [29] | CB-VC (46), CB & VC or ETO (44) | Biopsy + (ND), S: ND, prior CT/RT: excluded | TAC, Snellen | - | ND | -NF1: Age ≤ 5 years (OR 5.3; 95% CI: 1.0–26.7; P = 0.04) and (M)DC stage 3 (OR 7.1; 95% CI: 1.8–33.3; P = 0.006) -nNF1: No prognostic factor found |
Abbreviations: AC; actinomycin, BFP: binocular fixation preference; CB: carboplatin; CI: confidence interval; Cispl: cisplatin; DC: dactinomycin; ETO: etoposide; HOTV: HOTV eye test chart; (M)DC: (Modified) Dodge Classification; ND: no data; NF1: neurofibromatosis type 1; nNF1 No systemic association with neurofibromatosis type 1; P: P-value; PCZ: procarbazine; OR: odds ratio; RT: radiotherapy; SAT: Systemic Antitumor Therapy; SX: surgery; TAC: Teller Acuity Cards; TPCV: thioguanine, procarbazine, lomustine and vincristine; TX: treatment; VA: visual acuity; VB: vinblastine; VC: vincristine; VD: ventricular drain; VF: visual field
A: Results only available for total population that received SAT.
B: Subpopulation that received SAT